Compare ASNS & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASNS | IMNN |
|---|---|---|
| Founded | 1998 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 12.9M |
| IPO Year | 2022 | 1985 |
| Metric | ASNS | IMNN |
|---|---|---|
| Price | $3.04 | $4.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $50.00 | ★ $182.61 |
| AVG Volume (30 Days) | ★ 137.7K | 41.8K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,367,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $198.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.64 | $3.56 |
| 52 Week High | $17.80 | $41.22 |
| Indicator | ASNS | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 72.87 | 47.31 |
| Support Level | $2.86 | $3.87 |
| Resistance Level | $3.30 | $4.12 |
| Average True Range (ATR) | 0.28 | 0.25 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 82.04 | 58.55 |
Actelis Networks Inc is a networking solutions company with a mission to enable communication for Internet of Things, or IoT, projects, deployed over wide areas such as cities, campuses, airports, military bases, roads, and rail. Its networking solutions use a combination of newly deployed fiber infrastructure and existing copper and coaxial lines to create a cost-effective, secure, and quick-to-deploy network. Its solutions also offer end-to-end network security to protect critical IoT data, utilizing a powerful combination of coding and encryption technologies, applied as required on both new and existing infrastructure within the hybrid-fiber-copper network. The company operates as one operating segment: developing and marketing access broadband equipment for copper and fiber networks.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).